Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis.
A 68-year-old man with a 3-year history of rheumatoid arthritis (RA) developed gynecomastia 3 months after beginning oral low-dose methotrexate (MTX) therapy. Four months after MTX therapy was discontinued, the gynecomastia symptoms improved. Only eight cases of gynecomastia resulting from low-dose MTX administration have been reported worldwide, and no cases have previously been reported in Japan. Although it occurs infrequently, gynecomastia resulting from low-dose MTX therapy should be considered in male patients with RA.
Abe
Koki
K
Department of Orthopaedic Surgery, Chiba-Tokushukai Hospital, Funabashi, Japan. abeabeabe04@yahoo.co.jp
Mitsuka
Takeshi
T
Kanamori
Shigeo
S
Yamashita
Keishi
K
Yamaoka
Akiyoshi
A
D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006177:Gynecomastia / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D012074:Remission Induction; D016559:Tacrolimus / Q000627:therapeutic use; D028761:Withholding Treatment
D018501:Antirheumatic Agents; D016559:Tacrolimus; D008727:Methotrexate